Background: Bone metastases (BM) are rare in germ cell tumor (GCT) patients. Systematic data on risk factors, treatment and outcome are largely lacking.
Introduction
Bone metastases (BM) are rare in germ cell tumor (GCT) patients occurring in 3-9% at primary diagnosis [1] [2] [3] . According to the International Germ Cell Cancer Cooperative Group (IGCCCG) classification, the presence of BM classifies non-seminoma patients as 'poor prognosis', and seminoma patients as 'intermediate prognosis'. The predicted 5-year survival rates are 50% and 80%, respectively [4] .
Due to the low incidence of BM in GCT patients, data on patient characteristics, risk factors, treatment approaches, and outcome are scarce. To date, our knowledge is based on few retrospective cohort analyses, case reports and a retrospective subgroup analysis of patients with BM at first relapse from the International Prognostic Factor study group cohort [3, [5] [6] [7] [8] [9] .
The international G3 consortium of GCT experts intended to better define the impact of BM in GCT patients by an international database. Data of 123 bone metastatic GCT patients were collected to determine clinical characteristics and treatment outcome. Particularly, the impact of different treatment approaches comprising both standard dose chemotherapy (SD-CT) and high dose chemotherapy (HD-CT), as well as of additional local treatment approaches on the outcome of this subgroup, was tried to be better understood.
Methods-patients Study population
Anonymized data were collected retrospectively via case report forms from 23 expert centers across Europe and North America within the international G3 germ cell cancer consortium, and entered into a central database located at University Medical Center Eppendorf, Germany. In total, 140 patients with metastatic bone disease at primary GCT diagnosis between 1983 and 2013 were screened, 17 had to be excluded due to incomplete data. Study protocol and data processing were approved by Hamburg Ethical Board and by each participating center.
Inclusion criteria
Patients had to fulfill the following inclusion criteria: male sex, age >15 years; GCT defined either histologically or unequivocally high serum tumor markers (beta human chorionic gonadotropin [ß-hCG] or alpha-1-fetoprotein [AFP]); radiographic signs of bone metastases; and availability of baseline and follow-up information including treatment modalities to sufficiently calculate primary and secondary outcome variables.
Methods-statistics
statistical analysis. Progression-free survival (PFS) was the primary end point. PFS was defined from the start of primary chemotherapy until progression of disease or last follow-up. Patients dying without progression were censored at the time of death. The secondary end point overall survival (OS) was calculated from the onset of primary chemotherapy until death from any cause. Patients lost to follow-up were censored at the time of last visit. Covariates evaluated as prognostic factors were age, primary site, extent of BM, non-pulmonary visceral metastases, and tumor markers.
Calculation of correlations between different subgroups was performed using the v 2 test for categorical variables. Survival analysis was conducted using the method of Kaplan-Meier, the log-rank test was applied to compare survival estimates, and uni-/multivariate Cox regression analyses were run. The results were considered statistically significant whenever a two-sided P value <0.05 was achieved. All statistical analyses were conducted using SPSS software version 22 (IBM).
Results
A total of 123 patients with BM at primary diagnosis were eligible for analysis. Median age at primary diagnosis was 31 years (range, 15-77). Median follow-up was 18 months (range, 0-228; IQR, 57). BM most commonly affected the spine and pelvic bones in 71% and 24%, respectively, and less frequently other locations. A single BM was found in 48 patients (39%), whereas 75 (61%) had multiple bone manifestations. BM at primary diagnosis were mostly part of widespread metastatic disease with concomitant manifestations in the retroperitoneal and/or mediastinal lymph nodes, the lungs, liver and/or brain. Remarkably, 9% of patients had BM as the only site of metastatic disease apart from the primary tumor ( Table 1) .
Clinical characteristics
The clinical symptom most commonly reported was pain, whereas other bone-related complications such as pathologic fractures or spinal cord compression were extremely rare.
Primary treatment
Cisplatin-based combination SD-CT was applied as first-line treatment in 112 patients (91%), two received carboplatin-based first-line treatment, and one patient refused chemotherapy. Primary HD-CT followed by autologous stem cell transplantation was applied in eight patients (7%).
Additional localized treatment of residual bone lesions by secondary resection (SR) and/or radiotherapy (RT) was performed in 9 (7%) and 18 patients (15%), respectively.
Histological examination of resected bone lesions revealed necrosis/fibrosis, viable carcinoma, or mature teratoma in 5 (56%), 1 (11%) and 2 patients (22%), respectively (1 unknown). Of note, in 4 of 7 patients (57%), who underwent both SR of bone and nonbone residuals, histological findings were different in their resected specimens (supplementary Table S1 , available at Annals of Oncology online). All but one patient undergoing SR of BM with or without SR of other residuals achieved a secondary CR, two relapsed and subsequently died of their cancer. Additional local treatment of non-bone residual masses by SR and/or RT was applied in 43 patients (35%) and six patients (5%).
Objective responses (CR, marker-negative and positive PR) after primary treatment (including local treatments) were achieved in 93 patients (76%), whereas 28 (24%) had upfront disease progression. In addition to 10 CRs (7%) following chemotherapy alone, another 22 (18%) achieved CR by secondary local treatment accounting for a total CR rate of 25% (supplementary Table S2 , available at Annals of Oncology online).
Risk factor analysis
After a median follow-up of 18 months (range, 0-228, IQR 57), 54 patients (44%) had died: 40 (74%) of disease and 14 of other causes (i.e. infections, treatment related complications). The 2-year PFS and OS rates were 34% and 45% for the whole cohort. Estimated median PFS and OS were 21 months (range, 0-225) and 98 months (95% CI, 36-160). In multivariate analysis, PFS was significantly longer in seminoma patients (HR 0.33; 95% CI, 0.14-0.78). There was also a trend towards improved OS (HR 0.43; 95% CI, 0.13-1.03). Seminoma patients did not reach median PFS or OS with a 2-year PFS and OS rate of 68% and 75%, respectively. Non-seminoma patients had a median PFS and OS of 9 (95% CI, 5-13) and 31 months (95% CI, 0-83) resulting in 2-year PFS and OS rates of 24% and 36% (PFS, P ¼ 0.001; OS, P ¼ 0.013) ( Table 2 and supplementary Table S3 , available at Annals of Oncology online). Univariate analysis identified a mediastinal primary (HR 1.9; 95% CI, 1.1-3.5) and concomitant liver and/or brain metastases (HR 1.9; 95% CI, 1.1-3.2) as negative predictors for PFS. Mediastinal primary (HR 2.2; 95% CI, 1.1-4.1), and concomitant liver and/or brain metastases (HR 1.9; 95% CI, 1.1-3.3) were also negative predictors for OS (supplementary Figure S1 , available at Annals of Oncology online). In multivariate analysis, none of the aforementioned predictors remained statistically significant (Table 2 and supplementary Table S3 , available at Annals of Oncology online).
For seminomas, numbers of patients with a mediastinal primary or non-pulmonary visceral metastases or of patients receiving any other treatment than SD-CT were too small for adequate risk factor analyses (supplementary Tables S2 and S4 , available at Annals of Oncology online).
For non-seminomas, the only predictor for a lower risk of progression was secondary resection of non-bone residual masses in multivariable regression, which reduced the risk by 60% (HR 0.4; 95% CI 0.2-0.8). Non-seminoma patients undergoing additional RT of BM had a significantly increased risk of death (HR 2.2; 95% CI, 1.1-4.4) in multivariable analysis, but no significantly increased risk of progression (HR 1.3; 95%, 0.7-2.7). Secondary resection of BM did not significantly affect the risk of progression (HR 0.4; 95% CI, 0.1-1.4) or death (HR 1.0; 95% CI, 0.4-2.9) ( Table 3 and supplementary Figure S2 , available at Annals of Oncology online). The number of patients receiving primary HD-CT (n ¼ 7) was too small for adequate statistics.
Relapse after responding to primary treatment occurred in 32 patients (34%), 3 seminoma (12%) and 29 non-seminoma patients (42%), after a median interval of 7 months (range, 2-31; IQR 6). All relapsing patients had viable BM again. Despite the presence of BM at primary diagnosis and subsequent relapse, 12 of the 34 (38%) patients were alive at last follow-up, of which 9 patients were free of disease (28%) and 3 (9%) still had measurable disease.
Discussion
Overall, bone metastatic GCT patients have an unfavorable prognosis with a 2-year PFS and OS of 34% and 45%, respectively. Despite BM as an overall poor prognosticator, bone metastatic patients show differential outcomes depending on the absence or presence of other clinical risk factors. Not surprisingly, seminomatous histology was the strongest predictor for a favorable outcome with a 2-year PFS and OS of 68% and 75% as compared with non-seminoma patients with a 2-year PFS and OS of 24% and 36%, only. A mediastinal primary and the presence of liver and/or brain metastases were each associated with an excess risk of progression or death in univariate but not in multivariate Cox regression analysis of the whole cohort. Interestingly, the number of BM did not impact on PFS or OS either when comparing patients with a single BM (2-year PFS, 33%; 2-year OS, 42%) to those with multiple BM (2-year PFS, 35%; 2-year OS, 47%). To our knowledge, this analysis represents the largest cohort of male GCT patients with BM at primary diagnosis available. The present collection was realized by the international 'G3 collaboration' including many experts across Europe and North America, which limits the biases of regional or institutional preferences.
Seminoma patients
Outcome of seminoma patients with BM is almost comparable to the prognosis of the general seminoma 'intermediate prognosis' group (IGCCCG) with 2-year PFS and OS rates of 68% and 75%, respectively [4] . Interestingly, a high proportion of seminoma patients with BM had elevated ß-HCG (61%) and LDH levels (86%). ß-HCG elevation seems to be more frequent compared with the known frequency of about one-third in metastatic seminomas in general [10] . In line with previous studies [11] , this may reflect an increased total tumor mass, as BM were commonly part of widespread metastatic disease. This raises the question, if routine bone scans might be reasonable in seminoma patients with widespread metastatic disease and elevated ß-HCG, and if there was a cut-off value to guide such a decision.
The ORR of 86% and a relapse rate of 21% are satisfactory, and suggest a relatively good treatment sensitivity of seminomatous BM to platinum-based SD-CT. The role of secondary local treatments can only be discussed cautiously due to the limited number of patients undergoing additive interventions. In the recent analysis, no additive treatment approach seemed to significantly impact on PFS and OS, and thus chemotherapy alone may be considered sufficient.
Non-seminoma patients
Only about one-third of non-seminoma patients with BM may achieve long-term survival, which is clearly lower than the generally reported 50% long-term survival in the IGCCCG 'poor prognosis' category [4] . An estimated median PFS and OS of only 9 and 31 months, respectively, is dissatisfactory.
Kollmannsberger et al. had shown that outcomes of non-seminoma patients classified into the IGCCCG 'poor prognosis' category depend on the presence or absence of a hierarchy of clinical factors, e.g. lung metastases plus mediastinal GCT origin conferring the worst prognosis [12] . In line with this, we detected clinical risk factors predicting for differential PFS and OS in GCT patients with BM. In univariate analysis several factors were of borderline significance to negatively impact OS, but not PFS, i.e. mediastinal primary (HR 1.91, P ¼ 0.052), and presence of concomitant liver and/or brain metastases (HR 1.76, P ¼ 0.061). Similarly, a heterogeneous outcome has also been reported for patients with BM at first relapse identifying different risk factors [8] . This strengthens the hypothesis, that bone metastatic testicular cancer is a heterogeneous disease constellation and questions the reliability of BM alone as an overall poor prognostic feature. The extremely poor outcome in non-seminoma patients raises the question of how to improve treatment success. Nonrandomized phase II trials yielded excellent OS rates of 70-80% with up-front HD-CT in 'poor prognosis' patients [13] [14] [15] . However, twophase III trials failed to significantly improve outcomes of unselected poor prognosis patients by primary HD-CT [16, 17] .
Potential subgroups of poor prognosis patients, who may benefit from primary dose-intensification have been identified as those with inadequate marker decline after 1-2 cycles of primary SD-CT, primary mediastinal GCT and brain metastases [13, 18, 19] . Regarding bone-metastatic disease in particular, in a retrospective subgroup analysis of two phase II trials, 75% out of 40 poor prognosis non-seminoma patients with primary BM achieved long-term survival following HD-CT (plus secondary resection and/or irradiation of residual masses) [3] . Nevertheless, to date, there is no consensus regarding the general use of doseintensification in the first-line setting for patients with unfavorable risk factors [20, 21] . Unfortunately, the impact of HD-CT in nonseminoma patients with BM could not be determined here due to a limited number of only seven patients undergoing primary HD-CT.
In our cohort, secondary resection of non-bone residual masses, which is essential part of the established standard treatment for non-seminomas [20, 21] , significantly improved PFS (P ¼ 0.001), and showed a trend towards improved OS (P ¼ 0.13). Unfortunately, assessment of secondary local treatment approaches of bone residues was of limited explanatory power due to small patient numbers. SR of BM did not significantly impact PFS or OS, but seven of the nine patients remained disease free after a median follow-up of 13 months (IQR 66) with a median OS of 67 months (95% CI, 0-171). Moreover, five out of nine patients (56%) undergoing resection of BM residues displayed necrosis/fibrosis, which implies a reasonable effect of chemotherapy even on BM. This finding is in line with histological findings in otherwise localized residual masses in a retrospective analysis of non-seminoma patients [22] . In a previous analysis of GCT patients with BM undergoing HD-CT, all four patients undergoing SR of BM revealed necrosis [3] . However, teratoma manifestations and/or discordant histological findings between resected residual masses in and outside of the bone in our analysis argue towards the need for at least histological investigation of residual BM, whenever feasible. Discordant findings have also been reported for residual masses in the retroperitoneum and the thoracic cavity [23] .
The role of additional radiotherapy as additional local treatment also remains questionable, since our analysis shows a significantly inferior OS in non-seminoma patients undergoing BM irradiation (15 versus 73 months; P ¼ 0.026). Potential reasons for inferior outcomes after additional RT may be RT-related toxicity, disease-related features owing to the poor prognosis in general and/or a selection bias towards the use of additive radiotherapy in patients, where an excessive risk of progression has been assumed by the treating physicians. The latter two seem more likely given the commonly present wide-spread metastatic disease. RT-related toxicity instead seems less likely, although treatment-related toxicity was not part of the data collection.
Bisphosphonates are not routinely employed in these patients. A recent international consensus meeting did not give a recommendation for bisphosphonate in this rare clinical situation and we have thus not given a specific recommendation in the article.
Conclusion
The outcome of GCT patients with BM at primary diagnosis is heterogeneous depending on different clinical factors. Seminomatous histology was significantly predictive for a reduced risk of progression and the prognosis of seminoma patients with BM is comparable to that of the general IGCCCG 'intermediate prognosis' population. On the contrary, survival of non-seminoma patients with BM is worse than expected for the general IGCCCG 'poor prognosis' population. Despite lacking evidence of a survival benefit after additional resection of residual bone lesions, persisting vital carcinoma and/or teratoma still argue for a certain clinical relevance, but based on our database a general approach to additive irradiation of bone residuals is clearly not recommended. The final impact of treatment intensification and/or secondary local treatments cannot be answered by this database due to small patient numbers undergoing the specific interventions.
